Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01789957 · ClinicalTrials.gov registry record · Phase 3
Extension Study for 2993-112
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 225
- Enrollment target
NCT01789957 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 225 participants.
The verdict
NCT01789957, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 225 participants
- Enrollment target
Study Summary
This multicenter, open-label extension study of Protocol 2993-112 is designed to assess long-term glucose control as measured by HbA1c (glycosylated hemoglobin) and to evaluate long-term safety and tolerability in subjects treated with metformin who receive subcutaneously injected AC2993 (10 mcg) administered twice daily. Subjects completing Protocol 2993-112 are eligible to enroll.
Interventions
- DRUG AC2993
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 225 participants |
| Start Date | 2002-09 |
| Est. Completion | 2004-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01789957
The ClinicalTrials.gov registry entry for NCT01789957 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 225 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AC2993 is the first listed.
NCT01789957 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01789957 about?
NCT01789957 is a clinical study titled "Extension Study for 2993-112". This multicenter, open-label extension study of Protocol 2993-112 is designed to assess long-term glucose control as measured by HbA1c (glycosylated hemoglobin) and to evaluate long-term safety and tolerability in subjects treated with metformin who receive subcutaneously injected AC2993 (10 mcg) ad...
What is the current status of trial NCT01789957?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 225 participants. The study started on 2002-09. Estimated completion is 2004-06.
What interventions are being tested in trial NCT01789957?
The interventions under investigation include: AC2993 (DRUG).
Who is sponsoring clinical trial NCT01789957?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.